Product Description
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of California, Irvine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Colorectal Cancer
Phase 2: Breast Cancer
Phase 1: Adenocarcinoma|Bladder Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CIRCULATE-US | P3 |
Recruiting |
Colorectal Cancer |
2029-03-10 |
|
| NCT06529822 | P1 |
Not yet recruiting |
Bladder Cancer |
2028-11-30 |
|
| HEROES | P2 |
Recruiting |
Breast Cancer |
2027-12-15 |
|
| UCI 20-43 | P1 |
Recruiting |
Colorectal Cancer|Adenocarcinoma |
2025-12-31 |